{
  "protocolSection": {
    "armsInterventionsModule": {
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "recombinant interferon alfa",
          "description": "administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1",
          "armGroupLabels": [
            "Pancreatic Adenocarcinoma Patients"
          ],
          "otherNames": [
            "IFN alpha",
            "IFN-alpha-2b"
          ]
        },
        {
          "type": "DRUG",
          "name": "cisplatin",
          "description": "administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1",
          "armGroupLabels": [
            "Pancreatic Adenocarcinoma Patients"
          ],
          "otherNames": [
            "cisplatinum",
            "cis-diamminedichloroplatinum(II) (CDDP)"
          ]
        },
        {
          "type": "DRUG",
          "name": "fluorouracil",
          "description": "administered at a dose of 175 mg/m\\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3",
          "armGroupLabels": [
            "Pancreatic Adenocarcinoma Patients"
          ],
          "otherNames": [
            "5-FU"
          ]
        }
      ]
    }
  }
}